Transplantation, patient- and donor-related factors that influence treatment-related mortality and incidence of relapse. Arrows in parentheses: only moderate effect.
| . | TRM . | Relapse . | DFS . |
|---|---|---|---|
| *Including targeting busulfan and i.v busulfan | |||
| Abbreviations: TRM, treatment-related mortality; PBSC, peripheral blood stem cells; BM, bone marrow; Bu, busulphan; Cy, cyclophosphamide; TBI, total-body irradiation; CR, complete response | |||
| PBSC vs BM2,4 | ↔ | ( ↓ ) | (↑ ) |
| Bu*/Cy vs TBI/Cy2,5 –7 | (↓ ) | ( ↓ ) | (↑ ) |
| Intensified vs standard conditioning8,9 | ↑ | ↓ | ↓ |
| Dose-reduced vs standard conditioning12 | ↓ | ↑ | ↔ |
| Donor: HLA-ident sibling vs matched unrelated donor16,17 | ↓ | (↑ ) | ↑ |
| Donor: Syngeneic vs HLA-ident sibling20 | ↓ | (↑ ) | ↑ |
| Induction chemotherapy: if CR | ↓ | ↓ | ↑ |
| if no CR23,24 | ↑ | ↑ | ↓ |
| Comorbidities13 | ↑ | ↔ | ↓ |
| Higher age1 –3 | ↑ | (↑ ) | ↓ |
| Unfavorable cytogenetics39,40 | ↔ | ↑ | ↓ |
| . | TRM . | Relapse . | DFS . |
|---|---|---|---|
| *Including targeting busulfan and i.v busulfan | |||
| Abbreviations: TRM, treatment-related mortality; PBSC, peripheral blood stem cells; BM, bone marrow; Bu, busulphan; Cy, cyclophosphamide; TBI, total-body irradiation; CR, complete response | |||
| PBSC vs BM2,4 | ↔ | ( ↓ ) | (↑ ) |
| Bu*/Cy vs TBI/Cy2,5 –7 | (↓ ) | ( ↓ ) | (↑ ) |
| Intensified vs standard conditioning8,9 | ↑ | ↓ | ↓ |
| Dose-reduced vs standard conditioning12 | ↓ | ↑ | ↔ |
| Donor: HLA-ident sibling vs matched unrelated donor16,17 | ↓ | (↑ ) | ↑ |
| Donor: Syngeneic vs HLA-ident sibling20 | ↓ | (↑ ) | ↑ |
| Induction chemotherapy: if CR | ↓ | ↓ | ↑ |
| if no CR23,24 | ↑ | ↑ | ↓ |
| Comorbidities13 | ↑ | ↔ | ↓ |
| Higher age1 –3 | ↑ | (↑ ) | ↓ |
| Unfavorable cytogenetics39,40 | ↔ | ↑ | ↓ |